Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Edmonton man recreates iconic ‘A Charlie Brown Christmas’ tree

December 16, 2025

Alexa Plus’ website is live for some users

December 16, 2025

Halifax Water’s proposed increase amounts to ‘rate shock,’ regulatory board asks for adjustments

December 16, 2025

‘Twitter never left:’ X sues Operation Bluebird for trademark infringement

December 16, 2025

EVgo Accelerates Network Expansion with Domestically Made Prefabricated Charging Skids

December 16, 2025
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions
Press Release

U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions

By News RoomSeptember 24, 20245 Mins Read
U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions
Share
Facebook Twitter LinkedIn Pinterest Email
U.S. IVD And LDT For Autoimmune Diseases Market Research 2024-2030: Rising Awareness of Autoimmune Disorders Fuels Demand for Innovative Diagnostic Solutions

Dublin, Sept. 24, 2024 (GLOBE NEWSWIRE) — The “U.S. IVD And LDT For Autoimmune Diseases Market Size, Share & Trends Analysis Report By Type (IVD, LDT), By Technology (Immunoassays, Clinical Chemistry, Hematology, Coagulation, Microbiology), By Application, By Country, And Segment Forecasts, 2024 – 2030” report has been added to ResearchAndMarkets.com’s offering.

The U.S. IVD and LDT for autoimmune diseases market size is expected to reach USD 3.70 billion by 2030, growing at a CAGR of 4.8% from 2024 to 2030

The high prevalence of autoimmune disorders, growing awareness about these ailments, growing demand for technologically developed & high performance products, and high investments in research are the driving factors for the expanding growth of the market.

These health problems are second leading cause of chronic illness in the U.S. and are amongst the leading causes of deaths in the U.S. women. They have an adverse impact on the work productivity and the quality of life of patients and form an economic burden greatly affecting the healthcare spending in the U.S. The National Institute of Health estimates the direct healthcare costs associated with these disorders accounted for around USD 100 billion, whereas the cancer costs accounted for USD 57 billion.

A large number of people suffering from these disorders and rising prevalence at an alarming rate resulting in an increase of healthcare spending in the U.S. are all priority concerns, and is thus are expected to drive growth. Furthermore, the complications resulting from such health hazards like damage to internal organs, loss of mobility, and risk of death make it crucial for early diagnosis and intervention of such conditions. The rising awareness about these conditions is expected to lead market growth.

It is believed by number of researchers that the increase in the number of autoimmune diseases globally is due to the genetic predisposition and environmental factors. But there is very little knowledge about what exactly in the environment triggers the occurrence of autoimmune diseases. and mainly focused on commercial kits that are widely used by laboratories.

The FDA regulates IVD as medical devices however in the past it did not use its authority to regulate LDT. The FDA later announced that it would enforce its medical device regulatory authority to regulate the LDTs. Some researchers believe that the FDA regulation on LDTs would lead to an increase in the time and cost required to develop the tests.

U.S. IVD And LDT For Autoimmune Diseases Market Report Highlights

  • In 2023, the IVD for rheumatoid arthritis was the leading segment with a revenue share of 12.14% and the LDT for rheumatoid arthritis had a share of 11.47%. The large number of diagnostic tests available for it as well as the high prevalence of the disease contributed to the market share.
  • In 2023, clinical chemistry was the leading segment with a market share of 32.37% in the IVD and 19.98% in the LDT. The diagnosis of autoantibodies in the blood is the most commonly employed diagnosis, thus contributing to the large share.
  • Crohn’s disease is projected to grow at the fastest CAGR over the forecast period

Companies Featured

  • Adaptive Biotechnologies Corporation;
  • Agilent Technologies Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux, Inc.
  • Corgenix, Inc.
  • Johnson & Johnson Services, Inc.
  • Microbix Biosystems Inc.
  • PerkinElmer, Inc.
  • SQI Diagnostics Inc.
  • Thermo Fisher Scientific Inc.

Key Attributes:

Report Attribute Details
No. of Pages 100
Forecast Period 2023 – 2030
Estimated Market Value (USD) in 2023 $2.67 Billion
Forecasted Market Value (USD) by 2030 $3.7 Billion
Compound Annual Growth Rate 4.8%
Regions Covered United States

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. U.S. IVD & LDT for Autoimmune Diseases Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. U.S. IVD & LDT for Autoimmune Diseases Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.2. PESTEL Analysis

Chapter 4. U.S. IVD & LDT for Autoimmune Diseases Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. IVD & LDT for Autoimmune Diseases Market: Type Movement Analysis, 2023 & 2030 (USD Billion)
4.3. IVD
4.4. LDT

Chapter 5. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. IVD & LDT for Autoimmune Diseases Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
5.3. Immunoassays
5.4. Clinical Chemistry
5.5. Hematology
5.6. Coagulation
5.7. Microbiology
5.8. Molecular Diagnostics
5.9. Other

Chapter 6. U.S. IVD & LDT for Autoimmune Diseases Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. U.S. IVD & LDT for Autoimmune Diseases Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
6.3. Addison’s Disease
6.4. Ankylosing Spondylitis
6.5. Alopecia Areata
6.6. Rheumatoid Arthritis
6.7. Systemic Lupus Erythematosus
6.8. Systemic Sclerosis
6.9. Psoriasis
6.10. Antiphospholipid Antibody Syndrome
6.11. Diabetes Type 1
6.12. Crohn’s Disease
6.13. Ulcerative Colitis
6.14. Narcolepsy
6.15. Multiple Sclerosis
6.16. Uveitis

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Categorization
7.3. Company Heat Map Analysis
7.4. Company Profiles
7.4.1. Participant’s Overview
7.4.2. Financial Performance
7.4.3. Product Benchmarking
7.4.4. Recent Developments/ Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/o94l6x

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • U.S. IVD And LDT For Autoimmune Diseases Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

EVgo Accelerates Network Expansion with Domestically Made Prefabricated Charging Skids

Vendasta Unveils Custom AI Employees to Redefine the Future of Work for Small Businesses Everywhere

Mutuum Finance (MUTM) Advances Through Roadmap Phase 2 as Phase 6 Enters 99% Allocation

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

Aurigo Unveils Masterworks 2026: Reimagined for Speed, Clarity, and AI-Powered Decision-Making

You Butter Believe It: Butter Consumption Hits Historic High as Yogurt, Cottage Cheese, and Ice Cream Notch Growth in 2024

Safe and Green Development Corporation Obtains 25% Pricing Increase on Recurring Compost Purchase Orders

.twin to Enter ICANN’s 2026 gTLD Application Round as Digital Twins Become Core to Global Infrastructure

GeeFi’s (GEE) Phase Reports Steady Growth Amid Market Chaos With Over $800K Raised in Less Than 2 Weeks

Editors Picks

Alexa Plus’ website is live for some users

December 16, 2025

Halifax Water’s proposed increase amounts to ‘rate shock,’ regulatory board asks for adjustments

December 16, 2025

‘Twitter never left:’ X sues Operation Bluebird for trademark infringement

December 16, 2025

EVgo Accelerates Network Expansion with Domestically Made Prefabricated Charging Skids

December 16, 2025

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Vendasta Unveils Custom AI Employees to Redefine the Future of Work for Small Businesses Everywhere

December 16, 2025

Mutuum Finance (MUTM) Advances Through Roadmap Phase 2 as Phase 6 Enters 99% Allocation

December 16, 2025

Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era

December 16, 2025
Facebook X (Twitter) Pinterest TikTok Instagram
© 2025 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version